Estrogen Replacement Therapy Increases Plasma Ghrelin Levels
- 1 May 2005
- journal article
- clinical trial
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 90 (5), 2954-2963
- https://doi.org/10.1210/jc.2004-2016
Abstract
Ghrelin is a novel peptide hormone that has GH releasing activity and also other endocrine and metabolic functions. The purpose of this study was to investigate the effects of estrogen replacement therapy on plasma active ghrelin levels in 64 hysterectomized postmenopausal women receiving peroral estrogen (PE) or transdermal estrogen therapy for 6 months. Active ghrelin was measured using commercial RIA. Estrogen therapy increased plasma active ghrelin from 479 ± 118 to 521 ± 123 pg/ml (P = 0.002) among all the study subjects. PE therapy increased plasma ghrelin levels from 465 ± 99 to 536 ± 104 pg/ml (P = 0.001). Transdermal estrogen therapy did not increase plasma ghrelin levels significantly (from 491 ± 132 to 509 ± 138 pg/ml; P = 0.332). The relative changes in plasma ghrelin levels were associated with the relative changes in serum estradiol concentrations (r = 0.299; P = 0.017). During the estrogen therapy, negative associations were found between plasma active ghrelin levels and several plasma lipids (total cholesterol, low-density lipoprotein cholesterol, very low-density lipoprotein cholesterol, total triglycerides, and very low-density lipoprotein triglycerides). As a conclusion, estrogen replacement therapy increased active plasma ghrelin levels, particularly PE therapy. Additional studies are needed to determine the possible underlying mechanisms.Keywords
This publication has 66 references indexed in Scilit:
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With HysterectomyJAMA, 2004
- Effects of estrogen replacement therapy on natriuretic peptides and blood pressureMaturitas, 2004
- Effects of Postmenopausal Hormone Replacement Therapy on Insulin ResistanceEndocrine, 2002
- Regulation of plasma low density lipoprotein levels in postmenopausal women.Atherosclerosis, 2000
- Association of Hormone Replacement Therapy With Hemostatic and Other Cardiovascular Risk FactorsArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal WomenJAMA, 1995
- Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal womenThe Lancet, 1994
- Association of Hormone-Replacement Therapy with Various Cardiovascular Risk Factors in Postmenopausal WomenNew England Journal of Medicine, 1993
- Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal WomenAnnals of Internal Medicine, 1992
- Postmenopausal Estrogen Therapy and Cardiovascular DiseaseNew England Journal of Medicine, 1991